Paper Details

  1. Home
  2. Paper Details

Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients.

Author: DalencFlorence, Etienne-GrimaldiMarie-Christine, FerreroJean-Marc, LunarNastja, MacairePauline, MilanoGérard, PivotXavier, RoyerBernard, SchmittAntonin, ThomasFabienne

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study developed a population pharmacokinetic model for capecitabine and its three metabolites in patients with metastatic breast cancer. The study found that cytidine deaminase, alkaline phosphatase, and dihydrouracilemia levels were significant covariates influencing the pharmacokinetics of capecitabine and its metabolites. The study suggests that these factors should be considered when optimizing capecitabine treatment.
Paper Details　
Original Abstract of the Article :
PURPOSE: The present study was performed to examine relationships between systemic exposure of capecitabine metabolites (5-FU, 5'-DFCR and 5'-DFUR) and toxicity or clinical response in patients with metastatic breast cancer. METHODS: A population pharmacokinetic model for capecitabine and its three...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00280-020-04208-8

データ提供：米国国立医学図書館（NLM）

Population Pharmacokinetic and Pharmacodynamic Modeling of Capecitabine and Its Metabolites

This study aimed to understand the relationships between systemic exposure of capecitabine metabolites and toxicity or clinical response in patients with metastatic breast cancer. Researchers developed a population pharmacokinetic model for capecitabine and its three metabolites (5-FU, 5'-DFCR, and 5'-DFUR) to analyze the pharmacokinetic and pharmacodynamic characteristics of capecitabine treatment.

Capecitabine Pharmacokinetics: A Complex Process

The study found that the pharmacokinetics of capecitabine and its metabolites are highly complex, involving a complex absorption process and interactions with various enzymes. The model identified statistically significant covariates, including cytidine deaminase, alkaline phosphatase, and dihydrouracilemia, which influenced the pharmacokinetics of capecitabine and its metabolites. It’s like unraveling the intricate network of pathways involved in the metabolism of capecitabine, revealing a complex desert ecosystem of enzymes and metabolic processes.

Optimizing Capecitabine Treatment Regimen

The study's findings provide valuable insights into the pharmacokinetics and pharmacodynamics of capecitabine and its metabolites, which can be used to optimize treatment regimens and personalize therapy for patients with metastatic breast cancer. The model can help predict individual responses to capecitabine, guide dosage adjustments, and potentially minimize toxicity. It’s like using a carefully crafted map to navigate the intricate landscape of capecitabine therapy, ensuring a safe and effective journey for patients.

Dr.Camel's Conclusion

This research provides a detailed pharmacokinetic and pharmacodynamic model for capecitabine and its metabolites, revealing the intricate interplay of enzymes and metabolic processes involved in its therapeutic action. The model can be used to personalize therapy, optimize dosing, and minimize toxicity, potentially improving the effectiveness of capecitabine treatment for metastatic breast cancer. It’s like deciphering the hidden language of capecitabine metabolism, leading to a more personalized and effective approach to treatment.

Date :
  1. Date Completed 2023-03-15
  2. Date Revised 2023-03-15
Further Info :

Pubmed ID

33386926

DOI: Digital Object Identifier

10.1007/s00280-020-04208-8

Related Literature

Article Analysis
・Effects of floxuridine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.